Journal article
Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.
Abstract
BACKGROUND: Rituximab, a monoclonal anti-CD20 antibody, is increasingly used to treat idiopathic thrombocytopenic purpura (ITP).
PURPOSE: To systematically review the literature on the efficacy and safety of rituximab for the treatment of adults with ITP.
Authors
Arnold DM; Dentali F; Crowther MA; Meyer RM; Cook RJ; Sigouin C; Fraser GA; Lim W; Kelton JG
Journal
Annals of Internal Medicine, Vol. 146, No. 1, pp. 25–33
Publisher
American College of Physicians
Publication Date
January 2, 2007
DOI
10.7326/0003-4819-146-1-200701020-00006
ISSN
1056-8751